Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMELITO B R MALAPIRA

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1710914239
CMS profile
168018
Location
VIRGINIA BEACH, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$75,123.41

126 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $42,977.10 93
Allergan Inc. $32,146.31 33

Page 1 of 3; records 1–50 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMELITO B R MALAPIRA

NPI 1710914239 · CMS profile ID 168018

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

VIRGINIA BEACH, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 3; records 1–50 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710914239?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMELITO B R MALAPIRA, NPI 1710914239, CMS profile ID 168018. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710914239?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). AMELITO B R MALAPIRA, NPI 1710914239, CMS profile ID 168018. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710914239?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
AMELITO B R MALAPIRA, NPI 1710914239, CMS profile ID 168018, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 3; records 1–50 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1710914239?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

126 matching records · $75,123.41 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 126 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 126.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $3,562.5012/13/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657667659 CMS
Lilly USA, LLC $204.0012/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657665515 CMS
Lilly USA, LLC $699.0012/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657668281 CMS
Lilly USA, LLC $254.0012/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657668195 CMS
Lilly USA, LLC $25.0012/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709004643 CMS
Lilly USA, LLC $6.2512/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709004645 CMS
Lilly USA, LLC $4.1312/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709004647 CMS
Lilly USA, LLC $137.0012/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709004789 CMS
Lilly USA, LLC $9.9012/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709004791 CMS
Lilly USA, LLC $1.0412/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709004793 CMS
Lilly USA, LLC $2.5312/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709004929 CMS
Lilly USA, LLC $2.8112/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709004931 CMS
Lilly USA, LLC $5.6312/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709004933 CMS
Lilly USA, LLC $2.3012/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709005085 CMS
Lilly USA, LLC $72.6812/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709005087 CMS
Lilly USA, LLC $4.7812/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709005235 CMS
Lilly USA, LLC $22.5212/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709005237 CMS
Lilly USA, LLC $4.4612/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709005239 CMS
Lilly USA, LLC $39.6012/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709005241 CMS
Lilly USA, LLC $18.1712/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709005243 CMS
Lilly USA, LLC $21.1412/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709005245 CMS
Lilly USA, LLC $6.2512/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709005377 CMS
Lilly USA, LLC $10.6312/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709005379 CMS
Lilly USA, LLC $2.8112/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709005381 CMS
Lilly USA, LLC $16.5012/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709005383 CMS
Lilly USA, LLC $25.0012/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709005385 CMS
Lilly USA, LLC $1.8612/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709005545 CMS
Lilly USA, LLC $42.5012/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709005547 CMS
Lilly USA, LLC $8.1812/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709005549 CMS
Lilly USA, LLC $9.2112/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709005681 CMS
Allergan Inc. $116.6011/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670759507 CMS
Allergan Inc. $134.1211/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670759503 CMS
Lilly USA, LLC $20.0010/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657668925 CMS
Lilly USA, LLC $31.0010/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657668973 CMS
Lilly USA, LLC $1,500.0010/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657668923 CMS
Lilly USA, LLC $575.0010/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657668971 CMS
Lilly USA, LLC $14.9410/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657668297 CMS
Lilly USA, LLC $1,325.0010/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657668199 CMS
Lilly USA, LLC $1,500.0010/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657668611 CMS
Lilly USA, LLC $1,500.0010/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657668969 CMS
Lilly USA, LLC $455.2509/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657665005 CMS
Lilly USA, LLC $60.5009/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657667715 CMS
Lilly USA, LLC $445.9209/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657668279 CMS
Lilly USA, LLC $150.0809/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657668601 CMS
Lilly USA, LLC $4.8409/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657668619 CMS
Lilly USA, LLC $446.2509/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657668915 CMS
Lilly USA, LLC $8.2109/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657668927 CMS
Lilly USA, LLC $13.3109/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657668933 CMS
Lilly USA, LLC $1,500.0009/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657668295 CMS
Lilly USA, LLC $1,125.0009/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657668921 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $75,123.41 126
PY2020 $64,885.63 70
PY2021 $64,339.44 67
PY2022 $16,453.75 17
PY2023 $1,800.00 2
PY2024 $4,685.84 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $6,407.00 1
PY2024 Principal investigator $1,272.00 1
PY2023 Principal investigator $954.00 1
PY2022 Principal investigator $16,245.00 2
PY2021 Recipient $2,735.00 1
PY2021 Principal investigator $61,273.05 15
PY2020 Principal investigator $102,459.58 33
PY2019 Principal investigator $242,568.64 37

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

37 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $19,343.45 12/31/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE No dispute reported 06/30/2026 670122955
Principal investigator 1 Allergan Inc. $636.00 12/31/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670123101
Principal investigator 1 Allergan Inc. $22,509.83 12/31/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670127329
Principal investigator 1 Allergan Inc. $276.00 12/17/2019 Non-covered Recipient Entity
SENTARA NEUROLOGY SPECIALISTS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE No dispute reported 06/30/2026 670113919
Principal investigator 1 Allergan Inc. $4,886.80 12/16/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670112561
Principal investigator 1 Allergan Inc. $9,143.75 12/16/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE No dispute reported 06/30/2026 670112771
Principal investigator 1 Allergan Inc. $2,952.60 12/13/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670109793
Principal investigator 1 Allergan Inc. $12,413.65 11/20/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE No dispute reported 06/30/2026 670102895
Principal investigator 1 Allergan Inc. $5,137.60 11/13/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670096383
Principal investigator 1 Allergan Inc. $8,531.95 11/13/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670097017
Principal investigator 1 Allergan Inc. $666.24 10/31/2019 Non-covered Recipient Entity
SENTARA NEUROLOGY SPECIALISTS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670093121
Principal investigator 1 Allergan Inc. $16,331.45 10/23/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670090443
Principal investigator 1 Allergan Inc. $15,076.50 10/22/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE No dispute reported 06/30/2026 670089917
Principal investigator 1 Allergan Inc. $4,638.85 10/17/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670086899
Principal investigator 1 Allergan Inc. $7,816.60 10/07/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE No dispute reported 06/30/2026 670082657
Principal investigator 1 Allergan Inc. $8,500.00 09/20/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE No dispute reported 06/30/2026 670079001
Principal investigator 1 Allergan Inc. $500.00 09/20/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE No dispute reported 06/30/2026 670079005
Principal investigator 1 Allergan Inc. $13,287.65 09/19/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670078287
Principal investigator 1 Allergan Inc. $1,951.30 09/18/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670076319
Principal investigator 1 Allergan Inc. $8,500.00 09/01/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670071571
Principal investigator 1 Allergan Inc. $500.00 09/01/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670071575
Principal investigator 1 Allergan Inc. $1,308.15 08/27/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670070429
Principal investigator 1 Allergan Inc. $31,752.80 08/23/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670069121
Principal investigator 1 Allergan Inc. $8,500.00 08/01/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670063005
Principal investigator 1 Allergan Inc. $884.00 07/23/2019 Non-covered Recipient Entity
SENTARA NEUROLOGY SPECIALISTS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE No dispute reported 06/30/2026 670059822
Principal investigator 1 Allergan Inc. $9,388.85 07/16/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670057321
Principal investigator 1 Allergan Inc. $4,075.50 07/16/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE No dispute reported 06/30/2026 670057623
Principal investigator 1 Allergan Inc. $660.00 07/16/2019 Non-covered Recipient Entity
SENTARA NEUROLOGY SPECIALISTS
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670057697
Principal investigator 1 Allergan Inc. $172.00 07/16/2019 Non-covered Recipient Entity
SENTARA NEUROLOGY SPECIALISTS
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670057887
Principal investigator 1 Allergan Inc. $375.00 07/16/2019 Non-covered Recipient Entity
SENTARA NEUROLOGY SPECIALISTS
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670057939
Principal investigator 1 Allergan Inc. $12,884.85 06/25/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670053103
Principal investigator 1 Allergan Inc. $2,314.20 06/18/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE No dispute reported 06/30/2026 670051589
Principal investigator 1 Allergan Inc. $996.00 05/07/2019 Non-covered Recipient Entity
SENTARA NEUROLOGY SPECIALISTS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE No dispute reported 06/30/2026 670043825
Principal investigator 1 Allergan Inc. $289.68 04/30/2019 Non-covered Recipient Entity
SENTARA NEUROLOGY SPECIALISTS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670042029
Principal investigator 1 Allergan Inc. $4,099.25 04/23/2019 Non-covered Recipient Entity
SENTARA MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670039607
Principal investigator 1 Allergan Inc. $276.00 03/05/2019 Non-covered Recipient Entity
SENTARA NEUROLOGY SPECIALISTS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670028975
Principal investigator 1 Allergan Inc. $992.14 02/05/2019 Non-covered Recipient Entity
SENTARA NEUROLOGY SPECIALISTS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670022527